scholarly journals Therapeutic potential of opioid receptor heteromers in chronic pain and associated comorbidities

2021 ◽  
Author(s):  
Marion Gaborit ◽  
Dominique Massotte
Keyword(s):  
Chronic Pain ◽  
Opioid Receptor ◽  
Therapeutic Potential ◽  
Receptor Heteromers

The Therapeutic Potential of Novel Kappa Opioid Receptor-based Treatments

2020 ◽  
Vol 27 (12) ◽  
pp. 2012-2020 ◽  
Author(s):  
Sebastiano Mercadante ◽  
Patrizia Romualdi
Keyword(s):  
Chronic Pain ◽  
Opioid Receptor ◽  
Therapeutic Potential ◽  
Neurological Diseases ◽  
Experimental Studies ◽  
Kappa Opioid Receptor ◽  
Clinical Effects ◽  
Kappa Opioid ◽  
Peripheral Tissues

Introduction: Similarly to the μ opioid receptor, kappa opioid receptor (KOR), is present either in the central nervous system or in peripheral tissues. In the last years, several molecules, able to interact with KOR, have been the focus of basic research for their therapeutic potential in the field of chronic pain, as well as in depression, autoimmune disorders and neurological diseases. Discussion: The role of KOR system and the consequent clinical effects derived by its activation or inhibition are discussed. Their potential therapeutic utilization in conditions of stress and drug relapse, besides chronic pain, is presented here, including the possible use of KORagonists in drug addiction. Moreover, the potential role of KOR-antagonists, KOR agonistantagonists and peripheral KOR agonists is proposed. Conclusion: Other than pain, KORs have a role in regulating reward and mood. Due to its location, KORs seem to mediate interactions between psychiatric disorders, addiction and depression. Experimental studies in animal models have identified brain mechanisms that may contribute to clarify specific pathophysiological processes.

scholarly journals AB0953 CANNABINOIDS: FRIEND OR FOE OR A BYSTANDER?

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1774.2-1774
Author(s):  
N. Jain ◽  
N. Reddy ◽  
A. Moorthy
Keyword(s):  
Chronic Pain ◽  
Complementary Medicine ◽  
Health Care Professionals ◽  
Primary Care Physicians ◽  
Therapeutic Potential ◽  
Current Therapy ◽  
Common Diagnosis ◽  
Patient Reported ◽  
Ongoing Pain ◽  
Primary Physicians

Background:Cannabinoids has recently gained popularity for use in chronic pain. There is a lot of inquisitiveness among our patients wherein health care professionals are asked about its efficacy, side effects and sometimes even ask for a prescription! As there is paucity of data and research about its use in rheumatology, patient reported outcome(PROM) can guide ahead in expanding our knowledge and experience.Objectives:To study usage of cannabinoids by rheumatology patientsTo study awareness among primary physicians regarding Cannabinoid usage in rheumatology.Methods:Cross sectional survey with two arms. Arm 1 Information from patients attending tertiary rheumatology clinic,including perception regarding the use of Cannabinoids.Arm 2 consisted of collecting data via web-based survey with20-question from 100 GPs of Leicestershire. Questions on demographics, perspectives on and knowledge of cannabinoid use. Statistical analysis SPSS software.Results:Arm1 Total 102 rheumatology patients with 60%were females and 45% secondary education. 48% were unemployed. 75% Caucasians, 18% Asians. RA most common diagnosis followed by OA and FMS. 40 % depression and anxiety in addition to Rheumatic disease. 94% reported ongoing pain with 6-8 on a VAS scale. 79% were satisfied with their current therapy. 65% had heard about complementary medicine and 15% reported using cannabinoids.Most common form Cannabinoids oil 60% followed by smoking 20%. 56% reported using >3 months and majority 72% use daily. Median age 55 years. 88% users Caucasians. Mean disease duration 6.25 years among users indicates chronicity of disease has a direct proportion in usage. All users had ongoing pain of 7 on VAS. 87% believed it helps them managing pain effectively with a pain free state. On an average spends between 50-100 pounds per week. More than half believe cannabinoids should be available as a prescription drug in NHS and 30% interested to know more about it.In Arm 2 consisting of Primary care physicians, response rate 50%. Average clinical experience 5 years. Only 20% heard about usage of complementary medicine by rheumatology patient. Most replied that 10% of their patients use Cannabinoids for pain management. Most did not believe use of cannabinoids benefited the patients. Only 4% recommend its usage. 25% think it should be available as prescription. 40% experienced patients asking about cannabinoids during appointment. 88% of respondents did not know much about cannabinoid usage in rheumatology and have never prescribed it in their practice.Conclusion:Cannabinoids widely used by the rheumatology patients with PROM favouring its efficacy for control of chronic pain. Preclinical data suggest that cannabinoids might have a therapeutic potential RA1, OA, FMS2. Clinical data regarding cannabinoid treatment for rheumatic diseases are scarce, therefore, recommendations concerning cannabinoid treatment cannot be made. All patients who reported using it suffered from moderate to severe chronic pain. Thus main indication of usage was pain rather than recreational purpose. Although a small survey it clearly highlights lack of knowledge among primary physicians. These results emphasise the need for further research regarding the benefits and risks of cannabinoids in rheumatology.References:[1]RichardsonD. etal Characterisation ofthe cannabinoid receptor system in synovial tissue andfluid in patients with OA and RA Arthritis Res.Ther. 10, R43 (2008).[2]Walitt, B etal Cannabinoids for fibromyalgia. Cochrane DatabaseSyst. Rev. 7, CD011694 (2016).Disclosure of Interests:Nibha Jain: None declared, Neelima Reddy: None declared, Arumugam Moorthy Speakers bureau: Abbvie, Novartis,UCB,MSD

The therapeutic potential of Nrf2 inducers in chronic pain: Evidence from preclinical studies

2021 ◽  
pp. 107846
Author(s):  
Ya-Qun Zhou ◽  
Wei Mei ◽  
Xue-Bi Tian ◽  
Yu-Ke Tian ◽  
Dai-Qiang Liu ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Therapeutic Potential ◽  
Preclinical Studies

Class A GPCRs: Cannabinoid and Opioid Receptor Heteromers

2017 ◽  
pp. 173-206 ◽  
Author(s):  
Salvador Sierra ◽  
Ivone Gomes ◽  
Lakshmi A. Devi
Keyword(s):  
Opioid Receptor ◽  
Class A ◽  
Receptor Heteromers

scholarly journals Cannabinoids in Chronic Pain: Therapeutic Potential Through Microglia Modulation

2022 ◽  
Vol 15 ◽  
Author(s):  
Nynke J. van den Hoogen ◽  
Erika K. Harding ◽  
Chloé E. D. Davidson ◽  
Tuan Trang
Keyword(s):  
Chronic Pain ◽  
Immune Cells ◽  
Therapeutic Potential ◽  
Emotional Experience ◽  
Opioid Analgesics ◽  
Pain Modulation ◽  
Pain Outcomes ◽  
Cb2 Receptors ◽  
Affective Components ◽  
Peripheral Immune Cells

Chronic pain is a complex sensory, cognitive, and emotional experience that imposes a great personal, psychological, and socioeconomic burden on patients. An estimated 1.5 billion people worldwide are afflicted with chronic pain, which is often difficult to treat and may be resistant to the potent pain-relieving effects of opioid analgesics. Attention has therefore focused on advancing new pain therapies directed at the cannabinoid system because of its key role in pain modulation. Endocannabinoids and exogenous cannabinoids exert their actions primarily through Gi/o-protein coupled cannabinoid CB1 and CB2 receptors expressed throughout the nervous system. CB1 receptors are found at key nodes along the pain pathway and their activity gates both the sensory and affective components of pain. CB2 receptors are typically expressed at low levels on microglia, astrocytes, and peripheral immune cells. In chronic pain states, there is a marked increase in CB2 expression which modulates the activity of these central and peripheral immune cells with important consequences for the surrounding pain circuitry. Growing evidence indicate that interventions targeting CB1 or CB2 receptors improve pain outcomes in a variety of preclinical pain models. In this mini-review, we will highlight recent advances in understanding how cannabinoids modulate microglia function and its implications for cannabinoid-mediated analgesia, focusing on microglia-neuron interactions within the spinal nociceptive circuitry.

scholarly journals Activation of µ-δ opioid receptor heteromers inhibits neuropathic pain behavior in rodents

Pain ◽  
2020 ◽  
Vol 161 (4) ◽  
pp. 842-855 ◽  
Author(s):  
Vinod Tiwari ◽  
Shao-Qiu He ◽  
Qian Huang ◽  
Lingli Liang ◽  
Fei Yang ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Opioid Receptor ◽  
Pain Behavior ◽  
Receptor Heteromers ◽  
Δ Opioid Receptor

Brain opioid receptor density predicts motor cortex stimulation efficacy for chronic pain

Pain ◽  
2013 ◽  
Vol 154 (11) ◽  
pp. 2563-2568 ◽  
Author(s):  
Joseph Maarrawi ◽  
Roland Peyron ◽  
Patrick Mertens ◽  
Nicolas Costes ◽  
Michel Magnin ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Motor Cortex ◽  
Opioid Receptor ◽  
Receptor Density ◽  
Motor Cortex Stimulation
Sign in / Sign up

Export Citation Format

Share Document